

# Navigating Non-Physical Symptoms in MS


John A. Lincoln, MD, PhD

*Associate Professor of Neurology  
Bartels Family Professorship in Neurology  
Director, MRI Analysis Center  
Multiple Sclerosis Research Group*

# Disclosures

- I am currently on the Speaker's Bureau and have received honoraria from Sanofi-Genzyme, Biogen, Horizon, EMD-Serono
- I currently have grant funding from EMD-Serono

# Non-Physical Symptoms



# Pain

- Neurogenic – 50%-70%<sup>1,2</sup>
  - Paroxysmal – trigeminal neuralgia, Lhermitte's, tonic spasms, radicular pain
  - Persistent – burning dysesthesias limbs/trunk
    - Dysfunction of spinothalamic pathways
    - Damage to brain or spine - central pain
  - Pharmacologic Rx
    - Anticonvulsants, SNRI, TCA
    - Cannabinoids – subjective benefit to pain/spasticity large study<sup>3</sup>
  - Non-pharmacologic
    - Spinal cord stimulation
    - TENS, FES & rTMS<sup>4</sup>
- Non-neurogenic
  - Musculoskeletal or soft-tissue pain
  - May be related to spasticity

<sup>1</sup>Hirsh AT, Arch Phys Med Rehabil 2009;90:646–651; <sup>2</sup>Hadjimichael O, NARCOMS data. Health Qual Life Outcomes 2008;6:100;

<sup>3</sup>Zajicek JP, MUSEC trial. J Neurol Neurosurg Psychiatry 2012;83:1125–1132; <sup>4</sup>Cruccu G, Eur J Neurol 2007;14:952–970


# Depression

- Multifactorial causes\*
  - Psychological reaction to effects of disease
  - h/o depression
  - Fatigue
  - Lack of social support/social stress
  - Brain changes (ie. lesions/atrophy)
  - Immune dysregulation/endocrine abnormalities
  - DMTs – interferons
- Pharmacologic Rx
  - TCA, SSRI/SNRI
- Non-pharmacologic
  - CBT
  - Counselling/support structure

\*Wilken JA, Sullivan C, Neurologist 2007;13:343–354

# Fatigue

- Common symptom; severe in up to 74% patients<sup>1</sup>
- Mechanism unclear
  - Patients with active relapsing MS have severe fatigue more often than stable<sup>1</sup>
  - No clear relationship to progression<sup>2</sup>
- Fatigue vs. sleepiness
  - Sleepiness: propensity to fall asleep & effort to avoid sleeping
    - Sleep disorders
    - Polysomnogram required
- Motor fatigue: associated with but out of proportion to muscle weakness<sup>3</sup>
- Pharmacologic Rx
  - Amantadine
  - Modafinil
  - Aminopyridine
  - Amphetamine
- Non-pharmacologic
  - CBT
  - Treat underlying sleep d/o



<sup>1</sup>Hadjimichael O, NARCOMS data. Health Qual Life Outcomes 2008;6:100; <sup>2</sup>Koch M, MSJ 2008;14: 815–822; <sup>3</sup>Sehle, J Neuroeng Rehab, 2011;8:59

# Insomnia

- Dysfunctional sleep architecture
  - RLS, OSA or other sleep-related breathing d/o
  - Poor sleep hygiene
- Nighttime arousals
  - Frequent urination
  - Muscle spasms/pain
- Pharmacologic Rx
  - Short-acting sedative-hypnotics
  - Ramelteon
  - Melatonin
  - Trazadone
  - Sedating antihistamines
- Non-pharmacologic
  - Sleep hygiene
    - Relaxing routine 1 hr prior to bed
    - Cold environment
    - Regular morning exercise
    - Avoid late heavy meals
    - Avoid daytime napping
  - OSA
  - Sleep restriction for sleep-onset insomnia

# Insomnia – Sleep Restriction

- Designed to eliminate prolonged middle of the night awakening
- Restrict time in bed to actual sleep time
- Slowly increase time in bed
- Sleep restriction example
  - Person goes to bed at 11:00 pm and gets up at 8:00 am but only sleeps on average 6 hours per night
  - First step: restrict time in bed to only 6 hours (11:00 pm – 5 am)
  - Next step: gradually extend time spent in bed by 15-30 minutes as long as nighttime wakefulness remains minimal



# Cognitive Dysfunction

- Prevalence of 40%-80%<sup>1</sup>
- Areas of dysfunction<sup>2</sup>
  - Attention, processing speed & working memory
  - Executive dysfunction
  - Learning and memory
- Pharmacologic Rx
  - Memantine, donepezil, modafinil, amphetamine, dalfampridine<sup>3</sup>
- Non-pharmacologic
  - CBT/cognitive rehab
    - BrainHQ
    - COGNI-TRAcK
  - Physical exercise<sup>4</sup>

<sup>1</sup>Potagas C, J Neurol Sci 2008;267:100–106; <sup>2</sup>DeLuca J, Nat Rev Neuro, 2020;16:319-332; <sup>3</sup>Amato, J. Neurol. 2013;260:1452–1468;

<sup>4</sup>Motl, Mult Scler 2011;17:1034–1040

# Bladder Dysfunction

- Bladder
  - Control regions in frontal lobe, brainstem and spinal cord
  - Causes
    - Detrusor hyperactivity – urgency, frequency and urge incontinence
    - Detrusor Inefficiency – incomplete emptying, residual urine and frequency
    - Detrusor-sphincter dyssynergia – hesitancy, interrupted stream and incomplete emptying
  - Pharmacologic Rx
    - Anti-muscarinic Rx – oxybutynin, tolterodine
    - $\beta$ -adrenergic agonist - mirabegron
    - Botox injection in sphincter
  - Non-pharmacologic
    - Implanted electrical stimulation
    - rTMS of frontal pathways\*

\*Centonze D, Neurology, 2007;68:1045–1050

# Bowel Dysfunction

- Present in up to 2/3 patients<sup>1</sup>
  - Impaired mobility, drug side effects, altered diet
  - Constipation, fecal incontinence or both
- Pharmacologic Rx
  - Bulking agents – fiber supplements + hydration
  - Osmotic/stimulant laxatives
  - Pro-kinetic agents - linaclotide
  - Suppositories
- Non-pharmacologic
  - Kegel isometric exercises<sup>2</sup>
  - EMG biofeedback<sup>2,3</sup>
- Nutraceuticals
  - Swiss Kriss herbal laxative
  - 4 oz prune juice + slice of butter

<sup>1</sup>Preziosi G, Expert Rev Gastroenterol Hepatol 2009;3:417–423; <sup>2</sup>Lucio AD, Clinics. 2011;66:1563–1568; <sup>3</sup>Opara J, Fizjoterapia. 2011;19:41–49

# Sexual Dysfunction

- Causes
  - Female – reduced libido and/or vaginal dryness
  - Male – erectile dysfunction and/or reduced libido
    - Seen in up to 60% males with MS<sup>1</sup>
- Pharmacologic Rx
  - Phosphodiesterase-5 (PDE5) inhibitors – sildenafil, tadalafil
    - Several studies show benefit for male ED
    - Few studies show benefit for vaginal dryness<sup>2</sup>
  - $\alpha$ 2 antagonist – yohimbine
    - Not evaluated in controlled trials
  - SSRI may contribute
    - Bupropion may reduce sexual dysfunction caused by SSRI

<sup>1</sup>Zorzon M, Mult Scler 1999;5:418–427; <sup>2</sup>DasGupta R, J Urol 2004;171:1189–1193

# Conclusions

- Non-physical symptoms of MS are common
- Represent a large component of factors impacting quality of life
- Overlap between many non-physical symptoms
- Both pharmacologic & non-pharmacologic interventions

